In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and there were also early efficacy signals.
Scleroderma involves skin hardening and tightening, affecting blood vessels, internal organs and the digestive tract (Shutterstock)
Novartis and Chinese partner Abogen Biosciences’ messenger RNA-based T-cell engager has shown distinct differentiation in the clinic from other B-cell-depleting agents for autoimmune disorders, despite preliminary results generated from an investigator-initiated trial (IIT).
Key TakeawaysIn five patients with systemic sclerosis (scleroderma), Novartis/Abogen’s ABO2203, a subcutaneous mRNA-lipid nanoparticle, encoding CD19×CD3 T cell engager, caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, without steroid premedication.
The initial findings are expected to help speed up the upcoming company-sponsored studies of ABO2203, which Novartis acquired from Abogen…